Skip to main content

LaBarre Michael J.'s Form 4 filing

Halozyme Therapeutics, Inc. (HALO) · filed Sep 18, 2024

Accession no.
0001415889-24-023657
Filed
Sep 18, 2024
Trade date
Sep 17-18, 2024
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.25M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
LaBarre Michael J.CIK 0001507174Officer (SVP, CHIEF TECHNICAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 17, 2024Common StockMOption exerciseAcquired+10,000$16.65+$166,500183,756Direct
Sep 17, 2024Common StockSSaleDisposed−10,000$62.88−$628,800173,756Direct
Sep 18, 2024Common StockMOption exerciseAcquired+10,000$16.65+$166,500183,756Direct
Sep 18, 2024Common StockSSaleDisposed−7,963$61.89−$492,830.07175,793Direct
Sep 18, 2024Common StockSSaleDisposed−2,037$62.58−$127,475.46173,756Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 17, 2024Common StockMOption exerciseDisposed−10,000$0.00$021,861Direct
Sep 18, 2024Common StockMOption exerciseDisposed−10,000$0.00$011,861Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)